质子泵抑制剂与胃癌风险:基于人群的队列研究
中位随访5.0年后,PPI使用与胃癌风险较H2RA使用增加45%相关(HR 1.45,95%CI 1.06-1.98),但绝对风险仍低。
要点
- PPI新用户较H2RA新用户胃癌风险增加45%(HR 1.45,95%CI 1.06-1.98)。
- 治疗开始后5年和10年需伤害人数分别为2121和1191。
- 风险随累积用药时长、累积奥美拉唑当量和治疗开始后时间增加而升高。
核心结论
- PPI使用与胃癌风险较H2RA使用增加相关,但绝对风险仍低。
研究设计与样本
- 基于英国临床实践研究数据链的人群队列研究,采用新用户活性对照设计。
- 采用Cox比例风险模型估计胃癌风险比及95%置信区间,并用Kaplan-Meier法估计需伤害人数。
主要发现
- 中位随访5.0年后,PPI使用与胃癌风险较H2RA使用增加45%相关(HR 1.45,95%CI 1.06-1.98)。
- 治疗开始后5年和10年的需伤害人数分别为2121和1191。
- 风险比随累积用药时长、累积奥美拉唑当量和治疗开始后时间增加而升高。
- 结果在多个敏感性分析中一致。
临床怎么用
- 临床使用PPI时应权衡获益与潜在胃癌风险,避免不必要的长期使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether new users of proton pump inhibitors (PPIs) are at an increased risk of gastric cancer compared with new users of histamine-2 receptor antagonists (H2RAs). DESIGN: Using the UK Clinical Practice Research Datalink, we conducted a population-based cohort study using a new-user active comparator design. From 1 January 1990 to 30 April 2018, we identified 973 281 new users of PPIs and 193 306 new users of H2RAs. Cox proportional hazards models were fit to estimate HRs and 95% CIs of gastric cancer, and the number needed to harm was estimated using the Kaplan-Meier method. The models were weighted using standardised mortality ratio weights using calendar time-specific propensity scores. Secondary analyses assessed duration and dose-response associations. RESULTS: After a median follow-up of 5.0 years, the use of PPIs was associated with a 45% increased risk of gastric cancer compared with the use of H2RAs (HR 1.45, 95% CI 1.06 to 1.98). The number needed to harm was 2121 and 1191 for five and 10 years after treatment initiation, respectively. The HRs increased with cumulative duration, cumulative omeprazole equivalents and time since treatment initiation. The results were consistent across several sensitivity analyses. CONCLUSION: The findings of this large population-based cohort study indicate that the use of PPIs is associated with an increased risk of gastric cancer compared with the use of H2RAs, although the absolute risk remains low.
引用
- Abrahami D, McDonald EG, Schnitzer ME, et al. Proton pump inhibitors and risk of gastric cancer: population-based cohort study. Gut. 2021. PMID: 34226290. doi:10.1136/gutjnl-2021-325097
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。